Pluri (PLUR) Long-Term Deferred Tax (2014 - 2023)
Pluri (PLUR) reported Long-Term Deferred Tax of $84.9 million for Q2 2023, up 19.15% year-over-year from $71.3 million in Q2 2022, and up 19.15% quarter-over-quarter from $71.3 million in Q2 2022.
Pluri (PLUR) Long-Term Deferred Tax (2014 - 2023) Analysis & Trends
Pluri (PLUR) has 4 years of Long-Term Deferred Tax data on file, last reported at $84.9 million in Q2 2023.
- Long-Term Deferred Tax for Q2 2023 came in at $84.9 million, up 19.15% year-over-year; the trailing twelve-month figure through Jun 2023 was $84.9 million (up 19.15% YoY), and the FY2023 annual result was $84.9 million, up 19.15% from the prior year.
- Long-Term Deferred Tax improved to $84.9 million in Q2 2023 per PLUR's latest filing, from $71.3 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $84.9 million in Q2 2023 and troughed at $71.3 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Pluri | 21.39 Mn | 21.87 Mn | 86,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 84.90 Mn |
| Jun 30, 2022 | 71.25 Mn |
| Jun 30, 2015 | 29.24 Mn |
| Jun 30, 2014 | 21.00 Mn |